Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dr Matthew Snape is a guest on Sierra Leone's radio programme Pikin to Pikin Tok.

Matthew discusses the work of the Department's vaccine group on Ebola vaccines on 'Pikin to Pikin Tok' (which means child to child talk in the local language Krio), a radio series launched during the Ebola crisis. You can listen to the programme here.

The UK child rights agency 'Child to Child' and their partner in Sierra Leone, 'the Pikin to Pikin movement' were running a project in the east of Sierra Leone (in the impoverished Kailahun region where the first case of Ebola was reported) since 2011. This project aimed to enhance children's social, literacy, numeracy and life skills, but the Ebola crisis meant that the NGO's work, which required children to come together in groups, had to stop due to the health risk such gatherings would create.

'Child to Child' decided to turn to radio and commissioned radio producer Penny Boreham, who also works for BBC World Service, to produce the programmes about staying healthy during the crisis and its aftermath.

The radio project, which broadcasts Storytime programmes, music programmes and special programmes like this one on the new Ebola vaccines, is funded by Comic Relief and presented by Sierra Leonean storyteller, Usifu Jalloh.

Similar stories

Oxford Vaccine Group among winners at NHS Parliamentary awards

Researchers behind the Oxford AstraZeneca coronavirus vaccine have been recognised for their excellence at a healthcare awards ceremony.

New book highlights life-saving role vaccines play in prevention of killer diseases

'Brain Fever', a new book by internationally-renowned medical scientist Professor Richard Moxon, describes the decades of research that contribute to the development of vaccines for life-threatening illnesses such as meningitis, and how immunisation has been our greatest public health intervention.

Mixed Oxford/Pfizer vaccine schedules generate robust immune response against COVID-19, finds Oxford-led study

Alternating doses of the Oxford-AstraZeneca and Pfizer-BioNTech vaccines generate robust immune responses against COVID-19, according to researchers running the University of Oxford-led Com-COV study.

Delayed second dose and third doses of the Oxford-AstraZeneca vaccine lead to heightened immune response

Research on the ChAdOx1 nCoV-19, also known as the Oxford-AstraZeneca vaccine, indicates that a long interval between first and second doses does not compromise the immune response after a late second dose.

First trial participants vaccinated with Oxford COVID-19 variant vaccine

The University of Oxford in partnership with AstraZeneca began vaccinations on 27 June 2021 for a new phase in human trials to test a COVID-19 vaccine ‘AZD2816’ in volunteers against the B.1.351 variant of concern – commonly known as the Beta variant.

Oxford researchers identify levels of antibody protection required to prevent symptomatic COVID-19

Researchers from the University of Oxford have today released their findings about the so-called ‘correlates of protection’ against symptomatic COVID-19; potentially a tool to speed up safe development of new vaccines which may assist regulators in assessing the likely potency of any new COVID-19 vaccine without the need for Phase III efficacy trial data.